COLL · Collegium Pharmaceutical, Inc

$35.54 -0.54 (-1.50%) At close · Jul 20

Market Cap

$1.15B

32.43M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
David Dieter	General Counsel	$384,615	—	$3,189,732	—	$277,183	$18,562	$3,870,092
Colleen Tupper	CFO	$559,340	—	$2,484,486	—	$449,289	$21,940	$3,515,055
Scott Dreyer	Chief Commercial Officer	$523,236	—	$2,160,473	—	$335,563	$21,940	$3,041,212
Thomas Smith	Executive Vice President and Chief Medical Officer	$492,959	—	$1,620,314	—	$315,195	$17,540	$2,446,008
Vikram Karnani	CEO	$875,000	—	—	—	$835,406	$5,440	$1,715,846

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Vikram Karnani	CEO	$97,596	$500,000	$7,823,072	$2,228,622	$130,711	$124	$10,780,125
Shirley Kuhlmann	General Counsel	$525,270	$30,000	$2,300,770	—	$423,041	$22,215	$3,301,296
Colleen Tupper	CFO	$514,708	$30,000	$2,152,334	—	$470,733	$22,197	$3,189,972
Scott Dreyer	Chief Commercial Officer	$489,507	$30,000	$1,855,460	—	$394,252	$22,156	$2,791,375
Thomas Smith	Executive Vice President and Chief Medical Officer	$473,496	$30,000	$1,632,805	—	$346,052	$17,730	$2,500,083
David Dieter	General Counsel	—	—	—	—	—	—	—

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Shirley Kuhlmann	General Counsel	$490,412	—	$2,085,696	—	$278,438	$19,601	$2,874,147
Colleen Tupper	CFO	$485,574	—	$1,952,212	—	$275,063	$22,008	$2,734,857
Scott Dreyer	Chief Commercial Officer	$462,281	—	$1,918,841	—	$209,250	$22,008	$2,612,380
Thomas Smith	Executive Vice President and Chief Medical Officer	$451,428	—	$1,351,531	—	$224,235	$17,608	$2,044,802
Vikram Karnani	CEO	—	—	—	—	—	—	—
David Dieter	General Counsel	—	—	—	—	—	—	—

Executive changes

Person	Role	Change	Effective	Filed
Thomas Smith, M.D.	Executive Vice President and Chief Medical Officer	Terminated	—	2026-05-12
Scott Dreyer	Executive Vice President and Chief Commercial Officer	Terminated	2026-08-30	2026-05-12

Key facts CIK 1267565 CUSIP 19459J104 13F (30d) 22 filings 22 filers Visit website Investor relations